High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.05B
-5.75%
1.009
+180.36%
1.05B
-2.33%
1.081
-5.18%
1.08B
-2.03%
1.170
+36.01%
Estimates Revision
The market is revising Downward the revenue expectations for Illumina, Inc. (ILMN) for FY2025, with the revenue forecasts being adjusted by -2.24% over the past three months. During the same period, the stock price has changed by 4.42%.
Revenue Estimates for FY2025
Revise Downward
-2.24%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-6.16%
In Past 3 Month
Stock Price
Go Up
+4.42%
In Past 3 Month
17 Analyst Rating
0Wall Street analysts forecast ILMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 108.13 USD with a low forecast of 75.00 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
7 Hold
2 Sell
Moderate Buy
0Current: 89.470
Low
75.00
Averages
108.13
High
185.00
0Current: 89.470
Low
75.00
Averages
108.13
High
185.00
Canaccord
Kyle Mikson
Hold
maintain
$87 -> $99
2025-06-11
Reason
Canaccord
Kyle Mikson
Price Target
$87 -> $99
2025-06-11
maintain
Hold
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Illumina to $99 from $87 and keeps a Hold rating on the shares following a podcast session with CEO Jacob Thaysen. Thaysen commented that strong volume growth from clinical customers should help lead to increased revenue growth as pricing headwinds subside, and elaborated that the growth algorithm remains intact, although this will depend on continued adoption of the NovaSeq X, the analyst tells investors in a research note. Illumina appears positioned for improved execution over the medium-term, but Canaccord remains on the sidelines.
Piper Sandler
David Westenberg
Overweight
downgrade
$190 -> $185
2025-05-15
Reason
Piper Sandler
David Westenberg
Price Target
$190 -> $185
2025-05-15
downgrade
Overweight
Reason
Piper Sandler analyst David Westenberg lowered the firm's price target on Illumina to $185 from $190 following quarterly results. The firm keeps an Overweight rating on the shares.
UBS
Neutral
downgrade
$145 -> $98
2025-05-14
Reason
UBS
Price Target
$145 -> $98
2025-05-14
downgrade
Neutral
Reason
UBS lowered the firm's price target on Illumina to $98 from $145 and keeps a Neutral rating on the shares. The firm updated its forecasts to reflect academic and China pressures, the analyst tells investors in a research note.
Morgan Stanley
Tejas Savant
Equal Weight
downgrade
$136 -> $100
2025-05-12
Reason
Morgan Stanley
Tejas Savant
Price Target
$136 -> $100
2025-05-12
downgrade
Equal Weight
Reason
Morgan Stanley analyst Tejas Savant lowered the firm's price target on Illumina to $100 from $136 and keeps an Equal Weight rating on the shares. Q1 results were in line on better than expected instrument performance, which offset soft research consumables, the analyst tells investors. While valuation "isn't demanding," revised guidance reflects worsening of the academic end market and visibility on top-line reacceleration is key to upside, the analyst tells investors.
Canaccord
Kyle Mikson
Hold
downgrade
$92 -> $87
2025-05-12
Reason
Canaccord
Kyle Mikson
Price Target
$92 -> $87
2025-05-12
downgrade
Hold
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Illumina to $87 from $92 and keeps a Hold rating on the shares. The firm said they remain on the sidelines after they updated its 2025 guidance for multiple complicated headwinds that add further uncertainty to the company's return to growth mode.
JPMorgan
Neutral
downgrade
$120 -> $85
2025-05-09
Reason
JPMorgan
Price Target
$120 -> $85
2025-05-09
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Illumina to $85 from $120 and keeps a Neutral rating on the shares. The firm says that despite the solid Q1 results, the dynamic tariff environment, uncertainty on U.S. academic funding, export restrictions into China as well as evolving competitive dynamics limit the company's near-term visibility.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Illumina Inc (ILMN.O) is 19.67, compared to its 5-year average forward P/E of 84.42. For a more detailed relative valuation and DCF analysis to assess Illumina Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
84.42
Current PE
19.67
Overvalued PE
133.69
Undervalued PE
35.15
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
43.08
Current EV/EBITDA
13.29
Overvalued EV/EBITDA
62.65
Undervalued EV/EBITDA
23.52
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
8.43
Current PS
3.17
Overvalued PS
12.67
Undervalued PS
4.20
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ILMN News & Events
Events Timeline
(ET)
2025-06-15
20:10:20
Qiagen, Incyte announce collaboration to develop companion diagnostics
2025-05-08 (ET)
2025-05-08
16:06:42
Illumina cuts FY25 adjusted EPS view to $4.20-$4.30 from $4.50, consensus $4.46
2025-05-08
16:05:30
Illumina reports Q1 adjusted EPS 97c, consensus 94c
Sign Up For More Events
Sign Up For More Events
News
Preview
3.0
06-17NASDAQ.COMBuy, Sell, Or Hold Boston Scientific Stock At $100?
Preview
7.5
06-15NASDAQ.COMQIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers
Preview
7.5
06-15NewsfilterQIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
Sign Up For More News
People Also Watch
FAQ
What is Illumina Inc (ILMN) stock price today?
What is Illumina Inc (ILMN)'s business?
What is the price predicton of ILMN Stock?
What is Illumina Inc (ILMN)'s revenue for the last quarter?
What is Illumina Inc (ILMN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Illumina Inc (ILMN)'s fundamentals?
How many employees does Illumina Inc (ILMN). have?